150 related articles for article (PubMed ID: 9689189)
1. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of calcium supplementation on bone loss in perimenopausal women.
Elders PJ; Lips P; Netelenbos JC; van Ginkel FC; Khoe E; van der Vijgh WJ; van der Stelt PF
J Bone Miner Res; 1994 Jul; 9(7):963-70. PubMed ID: 7942164
[TBL] [Abstract][Full Text] [Related]
4. Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study.
Löfman O; Magnusson P; Toss G; Larsson L
Clin Chim Acta; 2005 Jun; 356(1-2):67-75. PubMed ID: 15936304
[TBL] [Abstract][Full Text] [Related]
5. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G
Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073
[TBL] [Abstract][Full Text] [Related]
7. Relationship between BMD, dental panoramic radiographic findings and biochemical markers of bone turnover in diagnosis of osteoporosis.
Vlasiadis KZ; Damilakis J; Velegrakis GA; Skouteris CA; Fragouli I; Goumenou A; Matalliotakis J; Koumantakis EE
Maturitas; 2008 Mar; 59(3):226-33. PubMed ID: 18342460
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
10. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
11. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal bone loss: does HRT always work?
Stevenson JC; Hillard TC; Lees B; Whitcroft SI; Ellerington MC; Whitehead MI
Int J Fertil Menopausal Stud; 1993; 38 Suppl 2():88-91. PubMed ID: 8252111
[TBL] [Abstract][Full Text] [Related]
13. Effect of isoflavones on lipids and bone turnover markers in menopausal women.
Schult TM; Ensrud KE; Blackwell T; Ettinger B; Wallace R; Tice JA
Maturitas; 2004 Jul; 48(3):209-18. PubMed ID: 15207886
[TBL] [Abstract][Full Text] [Related]
14. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
[TBL] [Abstract][Full Text] [Related]
15. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ipriflavone in established osteoporosis and long-term safety.
Agnusdei D; Bufalino L
Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
[TBL] [Abstract][Full Text] [Related]
17. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
18. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
19. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
